Literature DB >> 31864179

Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.

Hirotaka Ishida1, Alfred King-Yin Lam2.   

Abstract

There is a recent update in WHO classification of pancreatic neuroendocrine neoplasms (PanNENs). Our aim is to analyse the latest management for patients with PanNENs according to the current classification of these neoplasms. The primary treatment is curative surgery and the surgical procedures depend on size, location, and histopathology of the tumour. Even if tumour has metastases, debulking surgery or resection of the primary lesion could improve the prognosis of these patients. Systemic medication is indicated in patients with unresectable primary and/or distant metastatic lesions. As new antineoplastic agents have been approved in the last decade for the treatment of PanNENs, the clinical outcome is improving. However, the appropriate selection or the effective combination of drugs has not been fully established. To conclude, management of PanNENs depends on various factors and further development of treatment strategies is required for improvement of survival outcome of patients with PanNENs.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug; Pancreas; Pancreatic neuroendocrine carcinoma; Pancreatic neuroendocrine neoplasm; Pancreatic neuroendocrine tumour; Surgery

Mesh:

Substances:

Year:  2019        PMID: 31864179     DOI: 10.1016/j.critrevonc.2019.102835

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  9 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Authors:  Alfred King-Yin Lam; Hirotaka Ishida
Journal:  Histol Histopathol       Date:  2020-12-11       Impact factor: 2.303

3.  Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.

Authors:  Yuqing Qu; Haoming Li; Xianling Wang; Yulong Chen; Qinghua Guo; Yu Pei; Jin Du; Jingtao Dou; Jianming Ba; Zhaohui Lv; Yiming Mu
Journal:  Int J Endocrinol       Date:  2020-11-06       Impact factor: 3.257

4.  Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms.

Authors:  Rui He; Wunai Zhang; Shuo Chen; Yang Liu; Wenbin Yang; Junhui Li
Journal:  Front Genet       Date:  2020-11-27       Impact factor: 4.599

5.  Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Juwan Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  World J Gastrointest Oncol       Date:  2020-10-15

6.  Identification of a VHL gene mutation in atypical Von Hippel-Lindau syndrome: genotype-phenotype correlation and gene therapy perspective.

Authors:  Dali Tong; Yao Zhang; Jun Jiang; Gang Bi
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

7.  Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report.

Authors:  Goh Kian Guan; Subashini Rajoo; Noraini Mohd Dusa; Nik Hasimah Nik Yahya; Mohamed Badrulnizam Long Bidin
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-08-06

8.  Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.

Authors:  Liwen Hong; Yuan Wang; Tianyu Zhang; Chen Zhang; Lei Wang; Liying Wang; Zhengting Wang; Jie Zhong
Journal:  Med Sci Monit       Date:  2020-11-03

9.  Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism.

Authors:  Yidan Yan; Jianmin Xu; Guoxin Mao
Journal:  Med Sci Monit       Date:  2020-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.